Effects of proton pump inhibitor use on risk of Clostridium difficile infection: a hospital cohort study
- 116 Downloads
Although there are several studies on the association between use of proton pump inhibitors (PPIs) and increased Clostridium difficile infection (CDI) risk, detailed studies analyzing the effects of PPI use on CDI risk are lacking. The present study investigated the association of the dose, duration, and types of PPIs with CDI risk.
A single-center, cohort study was conducted on patients admitted to a hospital. The exposed cohort comprised patients who were prescribed PPIs at least once during the study period, and a control cohort was prepared by randomly assigning an index date to patients who did not use PPIs ensuring the same distribution of index dates as in the exposed cohort and matching sex, age, hospitalization period, and date of admission.
PPI use increased the risk of CDI by 1.8-fold [95% confidence interval (CI) 1.5–2.2]. CDI risk increased by 1.8-fold with esomeprazole (95% CI 1.4–2.2) and 2.0-fold with pantoprazole (95% CI 1.5–2.8). Patients who used a high dose had a higher risk than those who used a medium dose [adjusted hazard ratio (HR) 2.0 vs 1.3]. The risk of CDI increased 4.2-fold when the PPI exposure period was 6 days or shorter than 6 days.
Our study showed that PPI use was associated with an increased risk of developing CDI and the risk of CDI was dose dependent. Therefore, PPIs should only be used at proper doses and only for the necessary indications to avoid CDI risk.
KeywordsProton pump inhibitor Clostridium difficile Diarrhea
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 19.FDA Drug Safety Communication. Clostridium difficile associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). https://www.fda.gov/Drugs/DrugSafety/ucm290510.htm. Accessed 30 Dec 2018.
- 20.Lisi D. Pharmacotherapy self-assessment program 2018 BOOK1 infectious diseases. Lenexa: American College of Clinical Pharmacy; 2018.Google Scholar
- 22.Dexlansoprazole. https://www.pdr.net/drug-summary/Dexilant-dexlansoprazole-558.6197. Accessed 13 May 2019
- 24.Revaprazan hydrochloride. https://www.pharmacodia.com/yaodu/html/v1/chemicals/7ec2442aa04c157590b2fa1a7d093a33.html. Accessed 13 May 2019